Displaying publications 1 - 20 of 146 in total

Abstract:
Sort:
  1. Abdullah JM, Mutum SS, Nasuha NA, Biswal BM, Ariff AR
    Neurol. Med. Chir. (Tokyo), 2002 Jun;42(6):259-63.
    PMID: 12116532
    A 28-year-old Malay man presented with progressive paraparesis over a period of 6 months. Magnetic resonance imaging of the spine revealed a thoracic intramedullary spinal cord tumor at the T-7 level with homogeneous enhancement following intravenous gadolinium administration. Laminectomy and partial decompression of the tumor was performed. Histological examination of the tumor revealed features of spindle cell hemangioendothelioma. The patient was managed with limited field radiotherapy followed by systemic interferon therapy. Good neurological improvement was seen subsequently. The patient has survived 48 months with growth restraint at the primary site, although residual neurological deficit persists. Immunotherapy should be considered as a treatment modality for intramedullary hemangioendothelioma of the spinal cord after surgery and radiotherapy.
    Matched MeSH terms: Spinal Cord Neoplasms/radiotherapy
  2. Ahmad P, Khandaker MU, Muhammad N, Rehman F, Ullah Z, Khan G, et al.
    Appl Radiat Isot, 2020 Dec;166:109404.
    PMID: 32956924 DOI: 10.1016/j.apradiso.2020.109404
    The shortcomings in Boron neutron capture therapy (BNCT) and Hyperthermia for killing the tumor cell desired for the synthesis of a new kind of material suitable to be first used in BNCT and later on enable the conditions for Hyperthermia to destroy the tumor cell. The desire led to the synthesis of large band gap semiconductor nano-size Boron-10 enriched crystals of hexagonal boron nitride (10BNNCs). The contents of 10BNNCs are analyzed with the help of x-ray photoelectron spectroscopy (XPS) and counter checked with Raman and XRD. The 10B-contents in 10BNNCs produce 7Li and 4He nuclei. A Part of the 7Li and 4He particles released in the cell is allowed to kill the tumor (via BNCT) whereas the rest produce electron-hole pairs in the semiconductor layer of 10BNNCs suggested to work in Hyperthermia with an externally applied field.
    Matched MeSH terms: Neoplasms/radiotherapy
  3. Al-Mohammed HI, Sulieman A, Mayhoub FH, Salah H, Lagarde C, Alkhorayef M, et al.
    Sci Rep, 2021 Jul 15;11(1):14557.
    PMID: 34267237 DOI: 10.1038/s41598-021-93342-1
    Worldwide, thyroid cancer accounts for some 10% of total cancer incidence, most markedly for females. Thyroid cancer radiotherapy, typically using 131I (T1/2 8.02 days; β- max energy 606 keV, branching ratio 89.9%), is widely adopted as an adjunct to surgery or to treat inoperable cancer and hyperthyroidism. With staff potentially receiving significant doses during source preparation and administration, radiation protection and safety assessment are required in ensuring practice complies with international guidelines. The present study, concerning a total of 206 patient radioiodine therapies carried out at King Faisal Specialist Hospital and Research Center over a 6-month period, seeks to evaluate patient and occupational exposures during hospitalization, measuring ambient doses and estimating radiation risk. Using calibrated survey meters, patient exposure dose-rate estimates were obtained at a distance of 30-, 100- and 300 cm from the neck region of each patient. Occupational and ambient doses were measured using calibrated thermoluminescent dosimeters. The mean and range of administered activity (AA, in MBq) for the thyroid cancer and hyperthyroidism treatment groups were 4244 ± 2021 (1669-8066), 1507.9 ± 324.1 (977.9-1836.9), respectively. The mean annual occupational doses were 1.2 mSv, that for ambient doses outside of the isolation room corridors were found to be 0.2 mSv, while ambient doses at the nursing station were below the lower limit of detection. Exposures to staff from patients being treated for thyroid cancer were less compared to hyperthyroidism patients. With a well-defined protocol, also complying with international safety requirements, occupational exposures were found to be relatively high, greater than most reported in previous studies.
    Matched MeSH terms: Thyroid Neoplasms/radiotherapy*
  4. Alzoubi AS, Kandaiya S, Shukri A, Elsherbieny E
    Australas Phys Eng Sci Med, 2010 Jun;33(2):137-44.
    PMID: 20309667 DOI: 10.1007/s13246-010-0011-y
    Second cancer induction in the contralateral breast (CB) is an issue of some concern in breast radiotherapy especially for women under the age of 45 years at the time of treatment. The CB dose from 2-field and 3-field techniques in post-mastectomy chest wall irradiations in an anthropomorphic phantom as well as in patients were measured using thermoluminescent dosimeters (TLDs) at the local radiotherapy center. Breast and chest wall radiotherapy treatments were planned conformally (3D-CRT) and delivered using 6-MV photons. The measured CB dose at the surface fell sharply with distance from the field edge. However, the average ratio of the measured to the calculated CB dose using the pencil beam algorithm at the surface was approximately 53%. The mean and median measured internal dose at the posterior border of CB in a phantom was 5.47+/-0.22 cGy and 5.44 cGy, respectively. The internal CB dose was relatively independent of depth. In the present study the internal CB dose is 2.1-4.1% of the prescribed dose which is comparable to the values reported by other authors.
    Matched MeSH terms: Breast Neoplasms/radiotherapy*
  5. Ariza M, Rafaee T, Adeeb N, Muhaizan WM, Isa MR
    Med J Malaysia, 1999 Sep;54(3):371-3.
    PMID: 11045067
    A 14 year old girl presented in 1986 with a huge perineal swelling which was progressively increasing in size and associated with loss of weight and loss of appetite. Biopsy from the mass revealed rhabdomyosarcoma of the vulva. She was treated with chemotherapy and radium implant. She responded well to the regime. Fibrosis of the vulva and vagina caused difficulty in consummation. Once it was corrected, she conceived easily and proceeded to a normal pregnancy and delivery.
    Matched MeSH terms: Vulvar Neoplasms/radiotherapy*
  6. Azhar T, Kamada T, Lopez F, Harun R, Nor I, Lim A
    Med J Malaysia, 1991 Jun;46(2):123-8.
    PMID: 1839415
    One hundred patients with carcinoma of the cervix stages 1B to 4A were treated with intracavitary high dose rate radiation using a linear cobalt source. All cases have received external beam pelvic irradiation to 4500cGy mid plane in twenty fractions over four weeks. The results in terms of patient compliance and convenience were good while acute and late morbidities were comparable to standard Manchester technique of low dose rate intracavitary therapy as practised in the Institute of Radiotherapy and Oncology General Hospital Kuala Lumpur. The four year actuarial survival rate is 76% for stage II and 48% for stage III. All three stage IV patients died within 1 year. Four out of seven stage I patients are alive (minimum follow-up 18 months, longest 43 months). One died of systemic spread at 33 months while one is lost to follow up.
    Matched MeSH terms: Uterine Cervical Neoplasms/radiotherapy*
  7. Azhar T, Lopez F
    Med J Malaysia, 1989 Jun;44(2):104-10.
    PMID: 2626118
    One thousand consecutive cases of carcinoma of the uterine cervix treated in the General Hospital Kuala Lumpur between January 1977 to December 1979 were studied. Epidemiological breakdown by race, age, parity, occupation, stage and histology of the disease were obtained. Treatment complications in survivors available for follow-up were analysed. The Chinese had the highest incidence, followed by the Indians and the Malays. Ninety six percent were squamous cell cancers, the remaining were adenocarcinomas. Eighty percent of patients were seen at an advanced stage (Stage IIB-IV). Late radiation complications were mainly proctitis, cystitis and fistula; (5%, 7.2% and 1.4% respectively). These figures are comparable to many centres but the incidence of cystitis is relatively higher. This is believed to be related to irradiation techniques in these cases.
    Matched MeSH terms: Uterine Cervical Neoplasms/radiotherapy*
  8. Azhar T, Singh P
    Med J Malaysia, 1988 Mar;43(1):40-3.
    PMID: 2468988
    Matched MeSH terms: Head and Neck Neoplasms/radiotherapy
  9. Baharudin A, Khairuddin A, Nizam A, Samsuddin AR
    J Laryngol Otol, 2009 Jan;123(1):108-13.
    PMID: 18452635 DOI: 10.1017/S0022215108002466
    Radiotherapy is an important treatment modality for head and neck tumours. One of its major drawbacks is post-treatment salivary gland hypofunction. This study was performed to objectively evaluate the salivary gland function in post-irradiated head and neck tumour patients.
    Matched MeSH terms: Head and Neck Neoplasms/radiotherapy*
  10. Banjade DP, Shrestha SL, Shukri A, Tajuddin AA, Bhat M
    Australas Phys Eng Sci Med, 2002 Sep;25(3):110-8.
    PMID: 12416587
    This is a study using LiF:Mg;Ti thermoluminescent dosimeter (TLD) rods in phantoms to investigate the effect of lack of backscatter on exit dose. Comparing the measured dose with anticipated dose calculated using tissue maximum ratio (TMR) or percentage depth dose (PDD) gives rise to a correction factor. This correction factor may be applied to in-vivo dosimetry results to derive true dose to a point within the patient. Measurements in a specially designed humanoid breast phantom as well as patients undergoing radiotherapy treatment were also been done. TLDs with reproducibility of within +/- 3% (1 SD) are irradiated in a series of measurements for 6 and 10 MV photon beams from a medical linear accelerator. The measured exit doses for the different phantom thickness for 6 MV beams are found to be lowered by 10.9 to 14.0% compared to the dose derived from theoretical estimation (normalized dose at dmax). The same measurements for 10 MV beams are lowered by 9.0 to 13.5%. The variations of measured exit dose for different field sizes are found to be within 2.5%. The exit doses with added backscatter material from 2 mm up to 15 cm, shows gradual increase and the saturated values agreed within 1.5% with the expected results for both beams. The measured exit doses in humanoid breast phantom as well as in the clinical trial on patients undergoing radiotherapy also agreed with the predicted results based on phantom measurements. The authors' viewpoint is that this technique provides sufficient information to design exit surface bolus to restore build down effect in cases where part of the exit surface is being considered as a target volume. It indicates that the technique could be translated for in vivo dose measurements, which may be a conspicuous step of quality assurance in clinical practice.
    Matched MeSH terms: Neoplasms/radiotherapy*
  11. Banjade DP, Raj TA, Ng BS, Xavier S, Tajuddin AA, Shukri A
    Med Dosim, 2003;28(2):73-8.
    PMID: 12804703
    Verification of tumor dose for patients undergoing external beam radiotherapy is an important part of quality assurance programs in radiation oncology. Among the various methods available, entrance dose in vivo is one reliable method used to verify the tumor dose delivered to a patient. In this work, entrance dose measurements using LiF:Mg;Ti and LiF:Mg;Cu;P thermoluminescent dosimeters (TLDs) without buildup cap was carried out. The TLDs were calibrated at the surface of a water equivalent phantom against the maximum dose, using 6- and 10-MV photon and 9-MeV electron beams. The calibration geometry was such that the TLDs were placed on the surface of the "solid-water" phantom and a calibrated ionization chamber was positioned inside the phantom at calibration depth. The calibrated TLDs were then utilized to measure the entrance dose during the treatment of actual patients. Measurements were also carried out in the same phantom simultaneously to check the stability of the system. The dose measured in the phantom using the TLDs calibrated for entrance dose to 6-and 10-MV photon beams was found to be close to the dose determined by the treatment planning system (TPS) with discrepancies of not more than 4.1% (mean 1.3%). Consequently, the measured entrance dose during dose delivery to the actual patients with a prescribed geometry was found to be compatible with a maximum discrepancy of 5.7% (mean 2.2%) when comparison was made with the dose determined by the TPS. Likewise, the measured entrance dose for electron beams in the phantom and in actual patients using the calibrated TLDs were also found to be close, with maximum discrepancies of 3.2% (mean 2.0%) and 4.8% (mean 2.3%), respectively. Careful implementation of this technique provides vital information with an ability to confidently accept treatment algorithms derived by the TPS or to re-evaluate the parameters when necessary.
    Matched MeSH terms: Pelvic Neoplasms/radiotherapy*; Thoracic Neoplasms/radiotherapy*
  12. Bhoo-Pathy N, Pignol JP, Verkooijen HM
    Lancet, 2014 Nov 22;384(9957):1846.
    PMID: 25457914 DOI: 10.1016/S0140-6736(14)62239-X
    Matched MeSH terms: Breast Neoplasms/radiotherapy*
  13. Bhoo-Pathy N, Verkooijen HM, Wong FY, Pignol JP, Kwong A, Tan EY, et al.
    Int J Cancer, 2015 Nov 15;137(10):2504-12.
    PMID: 26018878 DOI: 10.1002/ijc.29617
    The value of adjuvant radiotherapy in triple-negative breast cancer (TNBC) is currently debated. We assessed the association between adjuvant radiotherapy and survival in a large cohort of Asian women with TNBC. Women diagnosed with TNBC from 2006 to 2011 in five Asian centers (N = 1,138) were included. Survival between patients receiving mastectomy only, breast-conserving therapy (BCT, lumpectomy and adjuvant radiotherapy) and mastectomy with radiotherapy were compared, and adjusted for demography, tumor characteristics and chemotherapy types. Median age at diagnosis was 53 years (range: 23-96 years). Median tumor size at diagnosis was 2.5 cm and most patients had lymph node-negative disease. The majority of patients received adjuvant chemotherapy (n = 861, 76%) comprising predominantly anthracycline-based regimes. In 775 women with T1-2, N0-1, M0 TNBCs, 5-year relative survival ratio (RSR) was highest in patients undergoing mastectomy only (94.7%, 95% CI: 88.8-98.8%), followed by BCT (90.8%, 95% CI: 85.0-94.7%), and mastectomy with radiotherapy (82.3%, 95% CI: 73.4-88.1%). The adjusted risks of mortality between the three groups were not significantly different. In 363 patients with T3-4, N2-3, M0 TNBCs, BCT was associated with highest 5-year RSR (94.1%, 95% CI: 81.3-99.4%), followed by mastectomy with radiotherapy (62.7%, 95% CI: 54.3-70.1%), and mastectomy only (58.6%, 95% CI: 43.5-71.6%). Following multivariable adjustment, BCT and mastectomy with radiotherapy remained significantly associated with lower mortality risk compared to mastectomy only. Overall, adjuvant radiotherapy was associated with higher survival in women aged <40 years, but not in older women. Adjuvant radiotherapy appears to be independently associated with a survival gain in locally advanced as well as in very young TNBC.
    Matched MeSH terms: Triple Negative Breast Neoplasms/radiotherapy*
  14. Biswal BM, Kumaraswamy N, Mukhtar F
    PMID: 15691157
    Between July 1999 to November 2000, 115 patients undergoing radiotherapy were evaluated for the development of treatment-related fatigue, using a modified Piper's fatigue scale. The above scale determines 4 dimensions of fatigue ie behavioral severity (6 items), affective meaning (5 items), sensory (5 items), and cognitive mood (6 items). Radiotherapy was delivered to the head and neck, breast, pelvis, and miscellaneous sub-sites. The area of the radiation field ranged from 25 to 480 cm2 (median 156 cm2). Forty-three percent of patients experienced significant fatigue, which altered their work environment. The individual components of fatigue were behavioral severity 25%, affective meaning 21%, sensory 18%, and cognitive mood 16%. Significant radiotherapy-related fatigue was higher in patients treated with advanced-stage disease, large radiotherapy field area, and low pre-radiotherapy hemoglobin level.
    Matched MeSH terms: Neoplasms/radiotherapy*
  15. Biswal BM, Sain AH, Othman NH, Baba A
    Trop Gastroenterol, 2002 Jul-Sep;23(3):134-7.
    PMID: 12693156
    Colorectal cancer is one of the most common malignancies in the West, but in Asia the incidence is low. However in Malaysia, colorectal cancer is increasing with a reported figure of 15% of all cancer cases. Adjuvant chemo and radiotherapy are now more frequently used in such patients. The present retrospective analysis was performed to document the effect of such therapy among patients with colorectal cancer in Malaysia.
    Matched MeSH terms: Colorectal Neoplasms/radiotherapy*
  16. Biswal BM, Zakaria A, Ahmad NM
    Support Care Cancer, 2003 Apr;11(4):242-8.
    PMID: 12673463
    BACKGROUND: The aim of this study was to evaluate the effect of pure natural honey on radiation-induced mucositis.

    PATIENTS AND METHODS: Forty patients diagnosed with head and neck cancer requiring radiation to the oropharyngeal mucosal area were divided in to two groups to receive either radiation alone or radiation plus topical application of pure natural honey. Patients were treated using a 6-MV linear accelerator at a dose rate of 2 Gy per day five times a week up to a dose of 60-70 Gy. In the study arm, patients were advised to take 20 ml of pure honey 15 min before, 15 min after and 6 h post-radiation therapy. Patients were evaluated every week for the development of radiation mucositis using the Radiation Therapy Oncology Group (RTOG) grading system.

    MAIN RESULTS: There was significant reduction in the symptomatic grade 3/4 mucositis among honey-treated patients compared to controls; i.e. 20% versus 75% ( p 0.00058). The compliance of honey-treated group of patients was better than controls. Fifty-five percent of patients treated with topical honey showed no change or a positive gain in body weight compared to 25% in the control arm ( p 0.053), the majority of whom lost weight.

    CONCLUSIONS: Topical application of natural honey is a simple and cost-effective treatment in radiation mucositis, which warrants further multi-centre randomised trials to validate our finding.

    Matched MeSH terms: Head and Neck Neoplasms/radiotherapy
  17. Biswal BM, Rath GK, Joshi RC, Mohanti BK, Ganesh T, Singh R
    Med J Malaysia, 1998 Mar;53(1):30-6.
    PMID: 10968134
    Radical radiotherapy is considered as the treatment of choice in locally advanced cancer cervix. In late stages radiotherapy produce optimum palliation and to some extent cure. Three hundred cases of cancer cervix (stage I-IV) comprising stage-I (7), stage-II (144), stage-III (145) and stage IV (4) were evaluated and treated with radiotherapy between April 1990 to July 1994. FIGO stage IB, IIA and IIB (early), were treated with predominant intracavitary radiotherapy (34 Gy X 2 fractions; within one week) followed by external pelvic radiotherapy to a dose of 36 Gy in 18 fractions; treating 200 cGy per fraction, 5 days a week. The late stage (stage-IIB, IIIA and IIIB, IVA) of disease were managed with initial external radiotherapy to a dose of 50 Gy, followed by a single intracavitary dose of 30 Gy to point-A. The median follow up was 33 months (range 12-72 months). The tumor volume less than 100 cc were associated with better survival than volume more than 100 cc (p < 0.05). The five year actuarial survival was 83%, 68% and 58% respectively in FIGO stage I-III disease. There were 0.33% and 2.6% late grade-III bladder and rectal complications. Our experience shows effectiveness of radiotherapy in the management of locally advanced cancer of the cervix.
    Matched MeSH terms: Uterine Cervical Neoplasms/radiotherapy*
  18. Brand Y, Lim E, Waran V, Prepageran N
    J Laryngol Otol, 2015 Dec;129(12):1243-7.
    PMID: 26412297 DOI: 10.1017/S0022215115002601
    Endoscopic endonasal techniques have recently become the method of choice in dealing with cerebrospinal fluid leak involving the anterior cranial fossa. However, most surgeons prefer an intracranial approach when leaks involve the middle cranial fossa. This case report illustrates the possibilities of using endoscopic techniques for cerebrospinal fluid leaks involving the middle fossa.
    Matched MeSH terms: Nasopharyngeal Neoplasms/radiotherapy*
  19. CHESTERMAN JN
    Med J Malaysia, 1963 Jun;17:263-8.
    PMID: 14060502
    Matched MeSH terms: Neoplasms/radiotherapy*
  20. Chai WL, Ngeow WC, Ramli R, Rahman RA
    Singapore Dent J, 2006 Dec;28(1):4-6.
    PMID: 17378334
    Head and neck cancer is becoming a more recognizable pathology to the general population and dentists. The modes of treatment include surgery and/or radiation therapy. Where possible, pretreatment dental assessment shall be provided for these patients before they undergo radiation therapy. There are occasions, however, whereby head and neck cancer patients are not prepared optimally for radiation therapy. Because of this, they succumb to complicated oral complications after radiation therapy. The management of xerostomia has been reviewed in Part I of this series. In this article, the management of dental caries, a sequalae of xerostomia following radiation therapy is reviewed.
    Matched MeSH terms: Head and Neck Neoplasms/radiotherapy*
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links